Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech
Pharmaceutical Technology
NOVEMBER 26, 2024
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Experimental Alzheimer’s Vaccine Shown to Delay Symptoms in Mice
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 3, 2023
An experimental vaccine that aims to slow down or prevent the progression of Alzheimer’s disease has been trialed in mice with promising early results. Mice engineered with genes that put them at greater risk of an Alzheimer’s-like disease had fewer amyloid plaques following the vaccine.
Vaccination 
246
246 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Malaria Could Be Eliminated by 2040: New Vaccine Offers Hope
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 8, 2023
The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.
Vaccination 246
246 
BioNTech Founders Predict Cancer Vaccine Is Only Years Away
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 16, 2022
The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.
Vaccination 242
242 
Extreme Case of Man Who Had 217 COVID Vaccines Surprises Scientists
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 12, 2024
That’s how many vaccines a man in Germany claims to have received for COVID-19 in just 29 months – and his body isn’t reacting the way some scientists thought it would. Two hundred and seventeen. The 62-year-old male from the city of Magdeburg made headlines a few years ago for his private and risky decision […]
Scientist 246
246 
India’s success story in pediatric vaccination program should be further replicated in adult vaccination: Experts
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 28, 2023
India’s success story in pediatric vaccination programme should be further replicated in the form of adult vaccination programme, experts recommended on the occasion of the 2nd edition of the India Vaccine Leaders Conclave (IVLC) held between August 22 and August 23, 2023 under the theme “Building Resilient Vaccine Ecosystems” in Mumbai.
Vaccination 189
189 
SEC recommends permission to SII for Omicron XBB 1.5 variant Covid-19 vaccine
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 14, 2024
A Subject Expert Committee (SEC), which advices the national drug regulator on approvals and clinical trials related to Covid-19 vaccines, has recommended grant of permission to Serum Institute of India (SII) for Omicron XBB 1.5 The vaccine variant […]
Vaccination 189
189 
ICMR and Panacea Biotec initiate phase 3 clinical trial for the first indigenous dengue vaccine, DengiAll
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 19, 2024
The Indian Council of Medical Research (ICMR) and Panacea Biotec have announced the initiation of the first-ever phase 3 clinical trial for a dengue vaccine in India. The trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
Clinical Trials 189
189 
SEC recommends approval for Zydus Lifesciences’ trivalent influenza vaccine in children
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 13, 2024
The Subject Expert Committee (SEC), which advises the Central drug regulator regarding clinical trials and approvals of drugs, has recommended approval for additional indication of Zydus Lifesciences’ inactivated trivalent influenza vaccine in children above six months with clinical trial waiver subject to condition.
Vaccination 188
188 
DBT to support multi institutional CoEs for nano-vaccines and nano-adjuvants development
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 14, 2022
The Department of Biotechnology (DBT) is extending support to the institutions and scientists to set up Centres of Excellence in the country for nano-vaccines and nano-adjuvants, to treat cancer and other diseases.The Department has invited Letters of Intent (LoIs) for ‘Setting up of CoE in Nano-Vaccines & Nano-Adjuvants’ for a period of five years (..)
Vaccination 189
189 
IISc develops heat-tolerant vaccine for protection against different strains of SARS-CoV-2 & future variants
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 22, 2024
The Indian Institute of Science (IISc) is now developing a heat-tolerant vaccine that can offer protection against different strains of SARS-CoV-2 – both current and future variants. The research […]
Vaccination 188
188 
IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents
XTalks
JANUARY 22, 2025
Valneva SE, who developed the worlds first FDA-approved chikungunya vaccine , has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus.
PETA India urges CPCSEA to withdraw recommendation for using stray dogs for vaccine testing
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 17, 2022
Animal rights organisation People for Ethical Treatment of Animals (PETA) India has urged the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) to withdraw its recent recommendations for using stray dogs for vaccine testing in favour of superior, human-relevant, animal-free research methods, which are more effective (..)
Vaccination 189
189 CDSCO declares sample of Bharat Biotech’s typhoid vaccine Typbar as NSQ
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 11, 2023
The Central Drugs Standard Control Organisation (CDSCO) has declared a batch of Typbar, the typhoid polysaccharide vaccine from Bharat Biotech International Ltd as not of standard quality (NSQ).
Vaccination 180
180 
DoP rejects Bharat Serums and Vaccines’ review petitions on ceiling price fixation of Hucog HP
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 25, 2023
The Department of Pharmaceuticals (DoP) has rejected review applications filed by the Maharashtra-based Bharat Serums and Vaccines Ltd against National Pharmaceutical Pricing Authority (NPPA) fixing the ceiling price of its infertility treatment drug brand Hucog HP, since the company did not file the petition within the prescribed time limit.
Vaccination 187
187 
Velocity Nominated for Two 2025 Vaccine Industry Excellence (ViE) Awards
Velocity Clinical Research
FEBRUARY 11, 2025
Velocity is a nominee for two 2025 Vaccine Industry Excellence (ViE) Awards! After winning the Best Clinical Trial Company ViE Award in 2024, we would be honored to receive your vote and once again share this recognition with you as we work to improve vaccine trials worldwide.
Vaccination 52
52 
Covid vaccine booster raises antibody levels in fight against Omicron
pharmaphorum
JANUARY 21, 2022
A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5
Antibody 115
115 
Can You Exercise After Flu Shot? What About Other Vaccines?
DM Clinical Research
SEPTEMBER 29, 2020
Annual flu shots are very important, as are other vaccines. While vaccines are quick and easy, they sometimes might require a little down-time. If you are dealing with a headache, fever, or nausea after your vaccine, then it is best to skip the gym. Are Vaccine Side Effects Normal? Vaccines Matter- Now More than Ever.
Vaccination 75
75 
COVID-19 vaccine development: Safety monitoring continues revolution in RWD
pharmaphorum
JULY 1, 2021
Miruna Sasu lays out how real-world data is evolving in the post COVID-19 vaccine reality. . Only a year after the emergence of COVID-19, a handful of life science companies started publishing data on the encouragingly high efficacy of their vaccine candidates. The speed with which these vaccines came to the public is remarkable.
Vaccination 103
103 
GSK’s Maria Reyes Boceta-Muñoz Talks Vaccine Development in a Post-Pandemic World
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
Vaccination 96
96 
Kaiser Permanente Joins Late-Stage Trial for Pfizer and BioNTech’s Lead COVID-19 Vaccine Candidate
XTalks
AUGUST 13, 2020
As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.
Vaccination 89
89 
Experimental COVID-19 vaccine offers long-term protection against severe disease
Medical Xpress
DECEMBER 1, 2022
In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)
Vaccination 75
75 
Behind the Scenes with a Study Coordinator for a Potential Breakthrough Breast Cancer Vaccine
ACRP blog
OCTOBER 10, 2023
In recognition of October being Breast Cancer Awareness Month , ACRP recently went behind the scenes with a clinical research coordinator on the study team for a bold Cleveland Clinic investigation of a vaccine aimed at preventing triple-negative breast cancer (TNBC), the most aggressive and lethal form of the disease.
Vaccination 111
111 
Researchers at IISc develop novel method to deliver vaccine candidate for TB
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 22, 2022
The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.
Vaccination 100
100 
Delhi HC quashes NPPA orders on overcharging against Bharat Serums and Vaccines and Bard Healthcare
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 28, 2022
The Delhi High Court has quashed four demand notices raised by the National Pharmaceutical Pricing Authority (NPPA) against Bharat Serums and Vaccines Ltd and medical devices manufacturer Bard Healthcare India Pvt Ltd for overcharging on non-scheduled drugs and medical devices, finding the move as unjustifiable as it does not allow rounding off principle (..)
Vaccination 100
100 
Video: Vaccine CARE Council Leader Mark Turner, MD
Velocity Clinical Research
MAY 21, 2024
“Next to clean water, vaccines are probably responsible for more saved lives than anything else we’ve done in medicine.” ” -Mark Turner, MD, Vaccine CARE Council Leader and Velocity Principal Investigator in Boise, ID.
Vaccination 52
52 
Video: Vaccine CARE Council Leader Shishir Khetan, MD
Velocity Clinical Research
APRIL 24, 2024
He’s also a leading expert for the Vaccine CARE Council. But as he explains in this video, he’s excited about the opportunities the CARE Council model is creating for investigators, even beyond vaccines. Shishir Khetan , MD, is a Principal Investigator and Senior Medical Director at Velocity.
Vaccination 52
52 
Coronavirus – How it Spreads and How Vaccines Work
My Local Study
MARCH 9, 2020
Read more Coronavirus – How it Spreads and How Vaccines Work. The post Coronavirus – How it Spreads and How Vaccines Work appeared first on MyLocalStudy.com. With substantial evidence contributing to the fear, the false information floating around further compounds the issue. Through reliable sources, we have.
Vaccine 72
72 
United States Vaccine Transport Market Report 2021: Focus on Hospitals, Epidemic Prevention Station, Pharmaceutical Manufacturers & Distributors, & Clinical Research Organizations – ResearchAndMarkets.com
BioTech 365
SEPTEMBER 16, 2021
United States Vaccine Transport Market Report 2021: Focus on Hospitals, Epidemic Prevention Station, Pharmaceutical Manufacturers & Distributors, & Clinical Research Organizations – ResearchAndMarkets.com United States Vaccine Transport Market Report 2021: Focus on Hospitals, Epidemic Prevention Station, Pharmaceutical Manufacturers (..)
Velocity Launches Vaccine Council to Accelerate Research Excellence (CARE)
Velocity Clinical Research
SEPTEMBER 14, 2023
Velocity has introduced the Vaccine Council to Accelerate Research Excellence (CARE). This council will bring world-class operational, patient recruitment, and trial conduct oversight to all Velocity sites conducting vaccine studies in the U.S. and Europe.
Vaccination 52
52 
Pneumococcal Vaccination for Adults: Conversation with Vaccine Scientists Dr. Heather Platt and Dr. Ulrike Buchwald from Merck – Xtalks Life Science Podcast Ep. 140
XTalks
DECEMBER 13, 2023
This episode features an interview with vaccine scientists and executives from Vaccines Global Clinical Development at Merck, Dr. Heather Platt, MD, Distinguished Scientist and Pneumococcal Vaccine Lead; and Dr. Ulrike Buchwald, MD, Scientific Associate Vice President, Global Clinical Research and Pneumococcal Vaccine Section Head.
Life Science 52
52 
Tyler Adam, MD, Coauthors NEJM Article With Results From Phase 3 Maternal RSV Vaccine Study
Velocity Clinical Research
APRIL 6, 2023
Tyler Adam, MD, Principal Investigator at Velocity Clinical Research in Hastings, NE , supported the promising MATISSE Phase 3 maternal RSV vaccine study — results of which have been published in the article, “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants” in the New England Journal of Medicine.
Vaccination 52
52 
Flu Vaccine vs. COVID-19 Vaccine
My Local Study
OCTOBER 1, 2020
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.
Vaccination 52
52 
Velocity Wins the 2024 Vaccine Industry Excellence Award for Best Clinical Trial Company
Velocity Clinical Research
APRIL 3, 2024
Velocity has won the 2024 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Company at The World Vaccine Congress in Washington, DC. The recognition is based on performance metrics, diversity of vaccine trial capabilities, and key initiatives to support vaccine research. and Europe.
Are There Any Alternatives to Vaccines?
DM Clinical Research
JANUARY 29, 2021
Vaccines are a hot topic during the best of times. However, with the COVID-19 vaccination, people are now discussing this topic more than ever before. Lots of people are even claiming that there are alternatives to vaccines, making these shots completely optional. Alternatives to Vaccines? Should Anyone Avoid Vaccines?
Vaccine 45
45 
Vaccines – Let’s Spread the Word
Imperical Blog
APRIL 15, 2021
The COVID-19 pandemic and the race for vaccines and treatments brought the topic of immunization into the living rooms of citizens across the world. Vaccines are making a difference. The campaign for COVID-19 vaccinations is the largest global vaccination effort ever executed. World Immunization Week is April 24-30.
Vaccination 59
59 
Brandon Essink, MD, CPI, is Lead Author of Article Providing Update on Zika Virus Vaccine Development
Velocity Clinical Research
JANUARY 20, 2023
Essink oversaw two phase 1 studies that evaluated the safety and immunogenicity of two mRNA-based Zika virus vaccines (Moderna’s mRNA-1325 and mRNA-1893) in adults.
Vaccination 52
52 
Leaders in Flu Defense: Insights into the 2024/25 Influenza Vaccine Strategy
XTalks
MAY 28, 2024
In a move signaling a major shift in influenza prevention strategies, CSL Seqirus, a global leader in flu vaccines, has transitioned from quadrivalent to trivalent formulations for the upcoming 2024/25 flu season in the US.
Vaccination 52
52 
HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins
XTalks
SEPTEMBER 21, 2023
announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease.
Vaccination 59
59 
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Pfizer
FEBRUARY 16, 2023
who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. OspA is a surface protein expressed by the bacteria when present in a tick.
Interested in an Investigational Vaccine to Potentially Protect Against Birth Defects? Join This Study Today!
Trialfacts
SEPTEMBER 15, 2022
About the Research Center: Study Location. Research Center: Crossroads Clinical Research. Location: Crossroads Clinical Research, 2700 Citizens Plaza, Suite 100, Victoria, TX, 77901. Lead Researcher: Richard H. Participants will receive an investigational vaccine against CMV infection at no cost.
Vaccination 52
52 
Did You Get 2 Doses of the Moderna COVID-19 Vaccine? This Study Could Be For You!
Trialfacts
SEPTEMBER 14, 2022
About the Research Center: Study Location. Research Center: Crossroads Clinical Research. Lead Researcher: Richard H. A vaccine works by making your body prepared to fight off infections if you come into contact with it. This study seeks to learn if these vaccines are helpful as preventative measures.
Vaccination 52
52 
Investigational COVID mucosal vaccine protects against disease and transmission
The Pharma Data
MAY 5, 2022
In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spread of the virus to other close contacts. The study, led by Duke researcher Stephanie N. The human vaccine is designed to be taken as a pill. Langel, Ph.D.,
Vaccination 52
52 
Vaccines – Let’s Spread the Word
Imperical Blog
APRIL 15, 2021
The COVID-19 pandemic and the race for vaccines and treatments brought the topic of immunization into the living rooms of citizens across the world. Vaccines are making a difference. The campaign for COVID-19 vaccinations is the largest global vaccination effort ever executed. World Immunization Week is April 24-30.
Vaccination 52
52 
Let's personalize your content